Kronos Bio Inc (KRON) - Total Assets
Based on the latest financial reports, Kronos Bio Inc (KRON) holds total assets worth $108.14 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Kronos Bio Inc - Total Assets Trend (2018–2024)
This chart illustrates how Kronos Bio Inc's total assets have evolved over time, based on quarterly financial data. Also see KRON stock market capitalisation for the company's overall valuation and market capitalisation.
Kronos Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Kronos Bio Inc's total assets of $108.14 Million consist of 92.7% current assets and 7.4% non-current assets. Review Kronos Bio Inc balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 68.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Kronos Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Kronos Bio Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kronos Bio Inc's current assets represent 92.7% of total assets in 2024, an increase from 83.6% in 2018.
- Cash Position: Cash and equivalents constituted 68.0% of total assets in 2024, down from 81.1% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Kronos Bio Inc Competitors by Total Assets
Key competitors of Kronos Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Kronos Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.93 | 8.32 | 13.34 |
| Quick Ratio | 12.93 | 8.32 | 13.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $93.99 Million | $139.33 Million | $76.35 Million |
Kronos Bio Inc - Advanced Valuation Insights
This section examines the relationship between Kronos Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.67 |
| Latest Market Cap to Assets Ratio | 0.43 |
| Asset Growth Rate (YoY) | -41.7% |
| Total Assets | $124.36 Million |
| Market Capitalization | $53.65 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kronos Bio Inc's assets below their book value (0.43x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Kronos Bio Inc's assets decreased by 41.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Kronos Bio Inc (2018–2024)
The table below shows the annual total assets of Kronos Bio Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $124.36 Million | -41.69% |
| 2023-12-31 | $213.28 Million | -27.69% |
| 2022-12-31 | $294.94 Million | -24.66% |
| 2021-12-31 | $391.48 Million | -23.53% |
| 2020-12-31 | $511.96 Million | +398.57% |
| 2019-12-31 | $102.69 Million | +714.06% |
| 2018-12-31 | $12.61 Million | -- |
About Kronos Bio Inc
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT in… Read more